

1 **Enhancer connectome in primary human cells reveals target genes of disease-
2 associated DNA elements**

3
4 Maxwell R. Mumbach^{1,2,12}, Ansuman T. Satpathy^{1,3,12}, Evan A. Boyle^{1,2,12}, Chao Dai^{1,12},
5 Benjamin G. Gowen^{4,5}, Seung Woo Cho¹, Michelle L. Nguyen⁶, Adam J. Rubin⁷, Jeffrey
6 M. Granja^{1,2}, Katelynn R. Kazane^{4,5}, Yuning Wei¹, Trieu Nguyen⁸, Peyton G.
7 Greenside², M. Ryan Corces¹, Josh Tycko², Dimitre R. Simeonov^{6,10}, Nabeela Suliman²,
8 Rui Li¹, Jin Xu¹, Ryan A. Flynn¹, Anshul Kundaje², Paul A. Khavari⁷, Alexander
9 Marson^{5,6,8}, Jacob E. Corn^{4,5}, Thomas Quertermous⁹, William J. Greenleaf^{1,2,8,11,13},
10 Howard Y. Chang^{1,7,13}

11
12 **AFFILIATIONS**

13
14 ¹ Center for Personal Dynamic Regulomes, Stanford University School of Medicine,
15 Stanford, CA 94305, USA

16 ² Department of Genetics, Stanford University School of Medicine, Stanford, CA 94305,
17 USA

18 ³ Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305,
19 USA

20 ⁴ Department of Molecular and Cell Biology, University of California, Berkeley, CA
21 94720, USA

22 ⁵ Innovative Genomics Institute, University of California, Berkeley, CA, 94720, USA

23 ⁶ Department of Microbiology and Immunology, University of California, San Francisco,
24 CA 94143, USA

25 ⁷ Program in Epithelial Biology, Stanford University School of Medicine, Stanford, CA,
26 94305, USA.

27 ⁸ Chan Zuckerberg Biohub, San Francisco, CA 94158, USA

28 ⁹ Department of Medicine, Division of Cardiovascular Medicine, Stanford University
29 School of Medicine, Stanford, California 94305, USA.

30 ¹⁰ Biomedical Sciences Graduate Program, University of California, San Francisco, CA
31 94143, USA

32 ¹¹ Department of Applied Physics, Stanford University, Stanford, CA, 94305, USA

33 ¹² These authors contributed equally

34 ¹³ These authors jointly directed this work

35
36 *To whom correspondence should be addressed. E-mail: howchang@stanford.edu and
37 wjg@stanford.edu

38

39

40

41

42

43

44

45 **ABSTRACT**

46

47 The challenge of linking intergenic mutations to target genes has limited molecular
48 understanding of human diseases. Here, we show that H3K27ac HiChIP generates
49 high-resolution contact maps of active enhancers and target genes in rare primary
50 human T cell subtypes and coronary artery smooth muscle cells. Differentiation of naïve
51 T cells to T helper 17 cells or regulatory T cells creates subtype-specific enhancer-
52 promoter interactions, specifically at regions of shared DNA accessibility. These data
53 provide a principled means of assigning molecular functions to autoimmune and
54 cardiovascular disease risk variants, linking hundreds of noncoding variants to putative
55 gene targets. Target genes identified with HiChIP are further supported by CRISPR
56 interference and activation at linked enhancers, by the presence of expression
57 quantitative trait loci, and by allele-specific enhancer loops in patient-derived primary
58 cells. The majority of disease-associated enhancers contact genes beyond the nearest
59 gene in the linear genome, leading to a four-fold increase of potential target genes for
60 autoimmune and cardiovascular diseases.

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89 Gene expression programs are intimately linked to the hierarchical organization
90 of the genome. In mammalian cells, each chromosome is organized into hundreds of
91 megabase-sized topologically associated domains (TADs), which are conserved from
92 early stem cells to differentiated cell types¹. Within this invariant TAD scaffold, cell type-
93 specific enhancer-promoter (E-P) interactions establish regulatory gene expression
94 programs². Standard methods require tens of millions of cells to obtain high-resolution
95 interaction maps and confidently assign E-P contacts³⁻⁵. Thus, the principles that
96 govern E-P conformation in disease-relevant patient samples are incompletely
97 understood. This gap in understanding is particularly problematic for interpreting the
98 molecular functions of inherited risk factors for common human diseases, which reside
99 in intergenic enhancers or other non-coding DNA features in up to 90% of cases⁶⁻⁹.
100 Such disease-relevant enhancers may not influence the expression of the nearest gene
101 (often reported as the default target in the literature), and instead act in a cell-type
102 specific manner on distant target genes residing up to hundreds of kilobases (kb)
103 away^{2,10-14}. Recently, systematic perturbations of regulatory elements in select gene loci
104 have shown that effects of individual regulatory elements on gene activity can be
105 predicted from the combination of (i) enhancer activity [marked by histone H3 lysine 27
106 acetylation (H3K27ac) level] and (ii) enhancer-target looping^{5,15}. Here we leverage this
107 insight to capture the combination of these two types of information genome-wide in a
108 single assay, mapping the enhancer connectome in disease-relevant primary human
109 cells.

110

111 RESULTS

112

113 H3K27ac HiChIP identifies functional enhancer interactions

114

115 We recently developed HiChIP, a method for sensitive and efficient analysis of
116 protein-centric chromosome conformation¹⁶. Cohesin HiChIP in GM12878 cells
117 identified similar numbers of loops as *in situ* Hi-C (~10,000) with high correlation ($R =$
118 0.83), demonstrating that HiChIP captures loops with high sensitivity and specificity.
119 Here, we evaluated the enhancer and promoter-associated mark H3K27ac¹⁷⁻¹⁹ as a
120 candidate factor to selectively interrogate E-P interactions genome-wide. We performed
121 H3K27ac HiChIP in mouse embryonic stem (mES) cells to compare to cohesin HiChIP
122 (**Supplementary Fig. 1a, Supplementary Table 1**)¹⁶. 3,552 of 4,191 H3K27ac HiChIP
123 loops in mES cells were also identified by cohesin HiChIP. The H3K27ac-biased loops
124 (\log_2 fold-change > 1) spanned shorter distances than cohesin-biased loops, and were
125 enriched for H3K27ac ChIP-seq peaks (78.9%; **Supplementary Fig. 1b-f, Supplementary Table 2**). Moreover, systematic titration of input material showed
126 H3K27ac HiChIP retained high signal fidelity and reproducibility from 25 million to
127 50,000 cells as input material (loop signal correlation = 0.918; **Supplementary Figs. 2 and 3**). Therefore, H3K27ac HiChIP identifies high-confidence chromatin loops focused
128 around enhancer interactions from limited cell numbers.

129

130 In order to capture (i) conformational change during T cell differentiation and (ii)
131 cell type-specific chromatin contacts of autoimmune risk variants in protective and

133 pathogenic T cell types, we performed H3K27ac HiChIP on primary human Naïve T
134 cells ($CD4^+CD45RA^+CD25^-CD127^{hi}$), regulatory T cells (T_{reg} ; $CD4^+CD25^+CD127^{low}$) and
135 T helper 17 cells (T_{H17} ; $CD4^+CD45RA^-CD25^-CD127^{hi}CCR6^+CXCR5^-$) directly isolated
136 from donors (**Fig. 1a,b and Supplementary Fig. 4a**)^{20,21}. T_{H17} cells were sorted to
137 include autoimmune disease-relevant pathogenic T_{H17} cells and to exclude follicular
138 helper T cells with a distinct surface phenotype and immune function (**Supplementary**
139 **Fig. 4a**)²²⁻²⁴. Peripheral blood $CD4^+$ T cells were isolated from three healthy subjects,
140 isolated by FACS, and subjected to H3K27ac HiChIP. HiChIP libraries from each subset
141 were high quality; greater than 40% of the reads represented unique paired-end tags
142 (PETs) (**Supplementary Fig. 4b-d and Supplementary Table 1**). Furthermore,
143 libraries exhibited high 1D signal enrichment at enhancers and promoters, and globally
144 recapitulated publically available H3K27ac ChIP-seq datasets (74.7% overlap of ChIP-
145 seq and 1D HiChIP peaks; **Fig. 1c**)²⁵. Inspection of the interaction matrix at
146 progressively higher resolution revealed chromatin compartments, TADs, and focal
147 loops, as previously reported in high-resolution Hi-C and HiChIP analyses from cell lines
148 (**Fig. 1b**)^{4,16}. Importantly, H3K27ac HiChIP maps were capable of identifying focal
149 interactions at 1 kb resolution, which is comparable to *in situ* Hi-C maps generated from
150 100-fold more cells and sequenced to 13-fold greater depth⁴ (**Fig. 1b**).

151 Previous saturation perturbation screens demonstrated that functional enhancers
152 can be identified by integrating H3K27ac ChIP-seq signal with chromosome
153 conformation contact strength (Hi-C)⁵. Since H3K27ac HiChIP combines these two
154 components into one assay, we reasoned that HiChIP signal, which we term Enhancer
155 Interaction Signal (EIS), should identify functional regulatory elements. To validate this
156 prediction, we first generated H3K27ac HiChIP maps in a chronic myelogenous
157 leukemia cell line (K562) as a direct comparison to published high-resolution CRISPR
158 interference (CRISPRi) screens⁵. We then examined the 3D enhancer landscape of the
159 *MYC* and *GATA1* loci using virtual 4C (v4C) analysis, where a specific genomic position
160 is set as an anchor viewpoint, and all interactions occurring with that anchor are
161 visualized in 2D¹⁶. v4C analysis of the *MYC* promoter demonstrated that EIS in K562
162 cells captured all functional enhancers identified in the CRISPRi screen (**Fig. 2a**).
163 Analysis of the *GATA1* locus demonstrated a similar agreement between both methods
164 (**Fig. 2b**). Quantitatively, EIS in K562 cells was significantly correlated with CRISPRi
165 score in the same cell type, whereas EIS in GM12878 (GM; B cell lymphoblast) cells
166 was not correlated with K562 CRISPRi (Spearman's rho = 0.332 and 0.145; p-value =
167 9.25×10^{-5} and 0.1246; **Fig. 2c**).

168 We found the enhancer landscapes of the *MYC* promoter to be highly cell-type
169 specific. v4C analysis of the *MYC* promoter in GM and My-La ($CD4^+$ T cell leukemia)
170 cells showed dramatically different regulatory interactions with the promoter compared
171 to K562 cells (**Fig. 2d**). To validate EIS specificity, we performed CRISPRi experiments
172 in GM cells using sgRNAs targeting enhancers identified in either GM or My-La HiChIP
173 maps as well as a positive control sgRNA targeting the *MYC* promoter and a negative
174 control sgRNA targeting lambda phage sequence (**Fig. 2e**). As expected, we found that
175 CRISPRi of GM, but not My-La, enhancers impacted *MYC* expression and cell growth in
176 GM cells (**Fig. 2e**).

177 Finally, we focused on the *CD69* locus, where a high-resolution CRISPRa screen
178 identified three enhancers upstream of the transcription start site²⁶. These sites were
179 also identified by Naïve T cell H3K27ac HiChIP. Moreover, HiChIP identified four
180 additional distal enhancers that were outside the region spanned by the sgRNA tiling
181 array (**Fig. 2f and Supplementary Fig. 5**). To functionally validate these novel
182 enhancers, we performed CRISPRa experiments in Jurkat cells with sgRNAs targeting
183 these enhancers, the *CD69* promoter, the *KLRF2* promoter as a locus negative control,
184 and a non-human genome-targeting negative control. We observed a significant
185 increase in *CD69* RNA and protein levels in the four HiChIP enhancers compared to
186 negative controls (**Fig. 2g and Supplementary Fig. 5**). Interestingly, two of the four
187 identified novel enhancers were within promoter regions of distant genes. These
188 findings are in line with previous reports that identified widespread distal gene regulatory
189 functions of promoters genome-wide^{27,28}. Altogether, these results suggest that
190 H3K27ac HiChIP EIS identifies functional regulatory elements, and that enhancers that
191 regulate a gene of interest can differ significantly between cell-types.
192

193 Landscape of enhancer interactions in primary T cells

194
195 We examined global features of the enhancer connectome associated with
196 cellular differentiation from Naïve T cells to either T_H17 cells or T_{reg} cells. We identified a
197 total of 10,706 high confidence loops in the union set of the three cell types
198 (**Supplementary Table 2**). Analysis of loop read support between biological replicates
199 demonstrated high reproducibility (**Supplementary Fig. 4c**), and ~91% of loop anchors
200 were associated with either a promoter or enhancer²⁹, as expected, with a median
201 distance of 130 kb (**Supplementary Fig. 6a,b**). Importantly, high-resolution E-P
202 connectivity maps revealed several features that could not be discerned from 1D
203 epigenomic data (i.e. H3K27ac ChIP-seq or ATAC-seq; **Fig. 3a**). These features
204 included: (i) ‘enhancer skipping’: enhancers that have stronger EIS with a more distal
205 target promoter, (ii) higher order structures such as ‘enhancer cliques’ (related to loop
206 cliques³⁰): multiple regulatory elements that have strong EIS with a single target
207 promoter, (iii) promoter to promoter interactions^{13,31}, and (iv) ‘enhancer switching’:
208 enhancers that exhibit differential EIS with a target promoter in a cell type-specific
209 manner (**Fig. 3a**).

210 We found that EIS contacts were very cell type-specific. After quantile-quantile
211 normalization of contact reads at high-confidence loops (correcting for false positives
212 caused by 1D fragment visibility; **Methods**), we focused on the top and bottom 5% of
213 EIS ranked by cell-type bias for each pair-wise comparison (**Supplementary Figs. 6c-g**
214 and **7, Supplementary Tables 3-4**). Cell type-specific enhancer loop anchors revealed
215 genes encoding canonical T cell subtype TFs and effector molecules (**Fig. 3b**,
216 **Supplementary Figs. 8 and 9**). Deeper v4C analysis of shared and cell type-specific
217 loci pinpointed regulatory elements interacting with each gene promoter of interest as
218 well as local conformational landscape changes (**Supplementary Figs. 8 and 9**). TF
219 motifs located within cell type-specific loop anchors were enriched for TFs known to
220 drive T cell subtype differentiation and nominated novel TFs involved in regulation (**Fig.**

221 **3c**). Furthermore, cell type EIS bias was associated with differential expression of genes
222 located within corresponding EIS anchors for the same cell type (Spearman's rho =
223 0.242 and 0.207; p-value = 4×10^{-15} and 2×10^{-11} ; **Fig. 3d**).

224 Cell type-specific EIS may be driven by cell type-specific enhancer activation
225 (based on H3K27ac ChIP-seq) or stable enhancer activation with cell type-specific
226 looping (Hi-C) in a gene specific manner. We first examined H3K27ac ChIP-seq at
227 differential EIS anchors and found that many biased H3K27ac HiChIP interactions also
228 exhibited biased ChIP-seq signal, as expected. 58.5% of Naïve-biased loops contain at
229 least one Naïve-biased ChIP-seq peak (\log_2 fold change > 1) located on the anchors.
230 Similarly, 66.7% of T_{H17} -biased and 67.8% of T_{reg} -biased interaction anchors were cell
231 type-specific in 1D (**Supplementary Fig. 10a**). Therefore, while on average ~64% of
232 the differential EIS corresponded to change in 1D data, ~36% were likely also driven by
233 change in 3D chromatin loop strength. To further assess the contribution of cell type-
234 specific 3D signal to EIS, we examined HiChIP 1D signal at differential EIS anchors. We
235 found that HiChIP 1D signal correlated better with ChIP-seq signal than EIS, with a
236 higher likelihood of differential ChIP-seq signal overlapping differential HiChIP 1D signal
237 compared to 3D, suggesting EIS bias is in part driven by 3D changes (**Supplementary**
238 **Fig. 10b**).

239 We asked whether the integration of reference cell line Hi-C data with primary T
240 cell H3K27ac ChIP-seq could recapitulate HiChIP EIS in primary T cells. We binned GM
241 Hi-C loops with increasing primary T cell ChIP-seq signal at loop anchors and then
242 determined the overlap of loops in each bin with loops derived from H3K27ac HiChIP.
243 As expected, increased ChIP-seq signal at the Hi-C anchors led to increased overlap
244 with the HiChIP loops. However, the overlap was lower in all T cell subtypes compared
245 to the same analysis performed using GM HiChIP data. These observations
246 demonstrate that cell-type specific 3D interactions can impact EIS independent of
247 differences in 1D ChIP-seq signal (**Supplementary Fig. 10c**). Similarly, previously
248 generated enhancer-promoter maps obtained from bulk T cells did not identify T cell
249 subtype-specific interactions obtained using H3K27ac HiChIP. To assess the unique
250 information obtained through cell type-specific interaction maps, we compared promoter
251 Capture Hi-C maps in bulk $CD4^+$ T cells to H3K27ac HiChIP maps in Naïve, T_{H17} , and
252 T_{reg} cells¹⁴. Strikingly, the most cell type-specific loops in T_{H17} and T_{reg} (16-fold
253 enriched) demonstrated a low discovery rate in promoter Capture Hi-C T cells (11.83%
254 in 415 loops and 13.83% in 373 loops, respectively; **Supplementary Fig. 10d**). Many of
255 these subset-specific interactions included genomic loci encoding functionally important
256 effector genes, such as *LRRC32*. The *LRRC32* locus contains T_{reg} -specific loops that
257 are neither visualized in HiChIP maps from Naïve or T_{H17} cells nor in bulk $CD4^+$
258 promoter Capture Hi-C maps (**Supplementary Fig. 10e**). Since primary human T_{H17}
259 and T_{reg} cells are present in human blood with low frequency, it would also be
260 challenging to generate subset-specific promoter Capture Hi-C maps with published
261 protocols. In summary, EIS is derived from a combination of 1D
262 ChIP-seq and 3D interaction signal and cannot be accurately predicted from 3D maps in
263 reference cell lines or unsorted primary cell datasets.

264 Cell type-specific EIS can occur at sites of shared chromatin accessibility. Paired
265 chromatin accessibility profiles by Assay of Transposase-Accessible Chromatin by
266 sequencing (ATAC-seq)³² from each T cell subset revealed most cell type-specific loop
267 anchors had equivalent chromatin accessibility across all three cell types (**Fig. 3e-g**). To
268 illustrate this finding, we examined the *BACH2* promoter, which exhibits shared
269 chromatin accessibility at enhancers, but increased EIS in Naïve cells (**Fig. 3e**).
270 Globally, only 14.2%, 27.8%, and 16.5% of Naïve-, T_H17-, and T_{reg}-biased loops,
271 respectively, contained at least one biased ATAC-seq peak (\log_2 fold change > 1)
272 located on the anchors. Furthermore, the majority of cell type-specific TF motifs were
273 observed in shared ATAC-seq peaks within differential interactions, highlighting that
274 these regions are functioning in T cell differentiation (**Fig. 3f-g**). Altogether, these results
275 suggest that in highly related – yet functionally distinct – cell types, a portion of
276 transcriptional control is achieved through differential chromosome looping, rather than
277 differential chromatin accessibility. This finding is consistent with previous studies which
278 demonstrated that T cell subset-specific TFs, such as Foxp3, act predominantly at pre-
279 accessible chromatin sites to establish subset-specific gene expression³³.
280

281 Enhancer interactions link disease variants to target genes

282

283 The high specificity of EIS enabled us to identify putative target genes of
284 autoimmune disease risk loci in functionally relevant T cell subsets. To achieve this, we
285 used a previously described list of putatively causal variants associated with 21
286 autoimmune diseases, known as PICS SNPs, which were fine-mapped based on dense
287 genotyping data²⁵. We determined that PICS autoimmune SNPs were significantly
288 enriched in T cell loop anchors, with specific autoimmune diseases showing greater
289 than 5-fold enrichment compared to a shuffled control loop set (**Supplementary Fig.**
290 **11**). Next, we constructed a set of all possible connections between autoimmune risk
291 SNPs and TSS within 1 Mb and measured the EIS for each SNP-TSS pair (**Fig. 4a**). We
292 aggregated these signals to determine the overall interaction activity in each T cell
293 subtype in each disease (**Fig. 4b**). We observed high interaction strength enrichments
294 and cell type specificity in autoimmune disease SNPs, but low enrichment and cell
295 specificity in non-immune traits (**Fig. 4b**). To further visualize HiChIP bias in shared or
296 differential enhancers, we analyzed SNP-TSS interactions grouped by their presence
297 near H3K27ac ChIP-seq peaks (**Supplementary Fig. 12a,b**). We observed a large
298 number of active SNP-TSS pairs that were present in regulatory regions that were
299 shared between T effector cell types (T_{reg} and T_H17), while relatively less EIS signal was
300 observed in SNPs located in cell-type specific enhancers, supporting the concept that
301 many autoimmune disease variants impact common T cell effector/activation
302 pathways^{25,34}. Notably, SNPs present in enhancers shared across all three cell types
303 could still be distinguished by HiChIP bias (**Supplementary Fig. 12a,b**). For example,
304 although we could not detect cell type bias at risk loci for Alopecia Areata using
305 H3K27ac ChIP-seq (**Supplementary Fig. 12a,b** and ref. 3), H3K27ac HiChIP identified
306 increased SNP-TSS activity in T_{reg} cells among shared T cell enhancers, consistent with
307 several studies identifying the crucial role of this cell type in disease pathogenesis³⁵.

308 Importantly, autoimmune signal enrichments were not readily apparent from 1D
309 H3K27ac ChIP-seq peaks, aggregated ChIP-seq signal within the TAD containing the
310 SNP, nor cell line H3K27ac HiChIP datasets (**Fig. 4b and Supplementary Fig. 12c**).
311 Therefore, examining 3D disease variant interactions may capture cell type biases more
312 robustly than 1D epigenomic data. Finally, to validate our findings with an orthogonal
313 dataset, we performed SNP-TSS EIS analysis on an overlapping set of autoimmune
314 disease-associated SNPs obtained from the NHLBI GRASP catalog and observed
315 similar enrichments of specific T cell subsets (**Supplementary Fig. 12d**).

316 We leveraged HiChIP to identify potential gene targets of intergenic SNPs, which
317 have classically been paired to the nearest neighboring gene. We overlapped the SNP-
318 TSS pairs with loops to call a discrete set of target pairs. We then performed differential
319 analysis on the SNP-TSS loops to ascertain bias for specific T cell subsets (**Fig. 4c and**
320 **Supplementary Table 5**). Examples of biased SNP-TSS pairs included *FOXO1* in
321 Naïve T cells (rs9603754), *BATF* (rs2300604) in Memory T cells, *CTLA4* (rs10186048)
322 in T_{reg} cells, and *IL2* (rs7664452) in T_{H17} cells (**Fig. 4c and Supplementary Table 5**).
323 Next, we sought to characterize the connectivity landscape of the SNP-TSS loops. We
324 identified an average of 1.75 gene targets per autoimmune SNP (ranging from 0 to over
325 10 target genes), while non-immune traits did not demonstrate an increase in targets
326 (0.33 genes per SNP; **Supplementary Fig. 12e**). For 684 autoimmune intergenic SNPs,
327 we identified a total of 2,597 HiChIP target genes, representing a four-fold increase in
328 target genes for known disease SNPs (**Fig. 4d**). Only 367 (~14%) of all targets were the
329 nearest gene to the SNP, while approximately ~86% of SNPs skipped at least one gene
330 to reach a predicted target TSS (**Supplementary Fig. 12e**). Furthermore, approximately
331 ~45% of SNP to HiChIP target interactions had increased signal compared to the same
332 SNP to nearest gene, despite distance biases.

333 334 Target gene validation by eQTL and CRISPRi

335
336 HiChIP enhancer-target gene interactions can be validated using previously
337 identified point mutations that alter expression at distantly located genes in T cells—i.e.
338 expression quantitative trait loci (eQTL)³⁶. For example, the celiac disease-associated
339 SNP rs2058660 impacts the expression of the inflammatory cytokine receptor genes
340 *IL18RAP*, *IL18R1*, *IL1RL1*, and *IL1RL2*, which are known regulators of intestinal T cell
341 differentiation and response³⁷. HiChIP EIS revealed contacts between rs2058660 and
342 each of these predicted gene promoters (**Supplementary Fig. 13a**). Similarly, the
343 Crohn's disease risk variant rs6890268 and the multiple sclerosis (MS) risk variant
344 rs12946510 impact the expression of *PTGER4* and *IKZF3*, respectively, and H3K27ac
345 HiChIP also demonstrated clear contacts between these SNPs and their predicted
346 promoter (**Supplementary Fig. 13a**). Globally, HiChIP contact signal was increased in
347 eQTLs in T cells compared to a distance-matched background loop set (p-value < 2.2 x
348 10⁻¹⁶; **Fig. 4e**) or to eQTLs identified in an unrelated cell type (liver; p-value < 2.2 x 10⁻¹⁶).
349 The overlap of HiChIP and eQTL loci provides support for chromosome interactions
350 as a physical basis for distal eQTLs¹⁰⁻¹² and further validates the HiChIP approach to
351 assign enhancer-target gene relationships.

352 We next sought to directly validate HiChIP SNP-gene targets using CRISPRi in
353 My-La cells. First, we focused on three loci of interest in primary T cells and then
354 confirmed that the SNP-TSS loops were also present in My-La cells (**Fig. 4f and**
355 **Supplementary Fig. 13b**). We then targeted sgRNAs to these SNP-containing
356 enhancers, as well as positive control sgRNAs to the HiChIP target gene promoters and
357 a negative control sgRNA targeting lambda phage sequence. As expected, we observed
358 a significant reduction of RNA levels in the HiChIP target genes upon CRISPRi of its
359 SNP-containing enhancer (**Fig. 4f**).
360

361 Fine-mapping of disease-associated DNA variants

362

363 Since SNP-TSS HiChIP signal is capable of identifying target genes of candidate
364 SNPs, we asked whether TSS-SNP HiChIP signals could also be used to nominate
365 functional causal variants within haplotype blocks in a reciprocal manner. We first
366 performed a proof-of-principle analysis using fine-mapped SNPs associated with
367 inflammatory bowel disease (IBD)³⁸ or Type 1 Diabetes (T1D)³⁹ as well as high
368 confidence PICS SNPs and examined EIS from putatively causal SNPs to all gene
369 promoters within 300 kb. EIS from putatively causal SNPs to gene promoters was
370 significantly higher than EIS from a distance-matched set of SNPs within the same LD
371 block to gene promoters (p -value = 2.4×10^{-15} , 8.7×10^{-8} , 3.9×10^{-3} for IBD fine-mapped
372 SNPs, T1D fine-mapped SNPs, and high confidence PICS, respectively; **Fig. 5a** and
373 **Supplementary Fig. 14a**). Next, we assessed the fine-mapping ability of HiChIP EIS at
374 individual loci of interest. We focused on IBD- and MS-associated SNPs neighboring the
375 *PTGER4* and *SATB1* loci and performed v4C analysis anchored at the gene promoters.
376 We calculated EIS signal at 1 kb resolution and identified specific regions within the
377 linkage disequilibrium (LD) blocks that contained the highest EIS to the target
378 promoters, positioning the likely causal SNPs within these regions (**Fig. 5b** and
379 **Supplementary Fig. 14b**). For example, at the *PTGER4* locus (**Fig. 5b**), the ~160 kb
380 genomic interval spanned by LD SNPs in association with Crohn's disease is refined to
381 two bins of 3kb and 4kb, which both contain PICS SNPs.
382

383 We asked whether complex disease-associated loci containing more than one
384 gene could be fine-mapped using HiChIP. We focused on two disease-associated
385 enhancers in between the *STAT1* and *STAT4* gene promoters (**Fig. 5c**). These two
386 genes encode transcription factors with distinct roles in immune regulation. Signal
387 transducer and activator of transcription 1 (STAT1) is critical for type I IFN and IFN γ
388 signaling, whereas STAT4 induces T H 1 differentiation and IFN γ expression⁴⁰. We
389 investigated bias of these enhancers to *STAT1* and *STAT4* and found that, despite
390 comparable linear distance and 1D signal at the promoters, the enhancers were
391 significantly biased to interact with *STAT4*. Next, we fine-mapped the disease
392 associated SNPs within this locus using 1 kb resolution EIS from the *STAT4* promoter,
393 and narrowed down candidate functional variants within the two enhancers (**Fig. 5c**). In
394 summary, HiChIP EIS can nominate functional causal variants within haplotype blocks,
395 and two-way analysis of target gene identification from an enhancer of interest and high-
resolution interaction maps of that enhancer with its target gene can be used to fine-

396 map disease-associated loci containing several candidate genes.
397

398 Allelic target gene bias of cardiovascular disease variants

400 Finally, we asked whether this approach could be applied broadly to other
401 categories of human disease, and whether we could directly test SNP-TSS associations
402 using allele-specific HiChIP. We generated high-resolution E-P maps from primary
403 human coronary artery smooth muscle cells (HCASMC), which can be used to inform
404 variants linked to cardiovascular diseases⁴¹. First, to validate cell type specificity, we
405 examined the *TCF21* gene promoter, a transcription factor required for the
406 differentiation of HCASMC⁴² and observed enrichment in HCASMC EIS relative to Naïve
407 T cells (Fig. 6a). We next examined the 9p21.3 locus, which harbors risk associations
408 with several cardiovascular disorders^{43–45}. We found that the promoters of all three
409 genes in the locus interact with one another and with CAD variant-containing enhancers
410 located approximately 100 kb upstream of the *CDKN2B* promoter (Supplementary Fig.
411 15). We then generated SNP-TSS target lists using CAD SNPs identified in the
412 CARDIoGRAMplusC4D study⁴⁶. We again performed differential analysis on the SNP-
413 TSS loops to ascertain bias for HCASMC versus Naïve T cells (Fig. 6b). Overall, 75.1%
414 of biased HCASMC SNP-TSS pairs were CAD SNPs, while only 5.5% of Naïve T cell
415 biased SNP-TSS pairs were CAD SNP-TSS loops. Next, we examined the connectivity
416 of the HCASMC SNP-TSS contacts and identified 1,062 gene targets, of which only 120
417 (~11%) mapped to the nearest gene. Furthermore, approximately 89% skipped at least
418 one gene to reach a predicted target TSS, and 64% of SNPs were mapped to more than
419 a single gene target.

420 We took advantage of genome phasing information in HCASMC to measure E-P
421 interactions at allele-specific CAD SNPs, allowing us to examine the functional
422 consequence of a risk variant compared to its alternative allele in the same nucleus.
423 First, 4.2% of high confidence loops in HCASMC with no observed mapping bias in the
424 anchors exhibited significant allelic bias (FDR < 0.05, Fig. 6c), consistent with
425 frequency of allelic imbalance of RNA expression and prior evidence of allele-specific
426 regulation of specific E-P interactions^{47,48}. We leveraged this global E-P allelic bias to
427 examine the effect of a risk variant compared to its control alternative allele for a set of
428 CAD-associated SNP-target gene pairs (Fig. 6d)⁴⁹. We found that many risk alleles
429 disrupt enhancer-target gene interactions, but a subset of pathogenic SNPs increased
430 enhancer-target gene interaction. At CAD risk variant rs1537373 in the 9p21.3 locus,
431 the risk allele (T) showed increased EIS to the *CDKN2A* promoter as well as an
432 additional enhancer within the lncRNA *ANRIL* relative to the reference allele (G) (Fig.
433 6e). We further observed increased EIS of the CAD risk variant rs4562997 to an
434 additional *SMAD3* enhancer 10 kb downstream of the TSS (Fig. 6e). The ability to
435 resolve enhancer connectomes of the risk and reference alleles in the same nucleus
436 demonstrates that the mutated base in the risk allele suffices to alter enhancer looping
437 in *cis* in disease-relevant primary cells.

438

439 DISCUSSION

440

441 Here, we developed an approach to define the high-resolution landscape of E-P
442 regulation in primary human cells. We find that E-P contacts are highly dynamic in
443 related cell types and often involve genomic elements with shared accessibility.
444 Accordingly, many complex features of the 3D enhancer connectome cannot simply be
445 predicted from 1D, which demonstrates that mapping conformation in primary cells can
446 identify novel regulatory connections underlying gene function in human disease. We
447 take advantage of this principle to chart the connectivity of autoimmune and
448 cardiovascular GWAS SNPs and link SNPs to hundreds of potential target genes.
449 Although non-genic SNPs have previously been paired with their closest neighboring
450 gene, we find that the majority of these variants can engage in long-distance
451 interactions, including skipping several promoters to predicted target genes, connecting
452 to multiple genes, or acting in concert with enhancer cliques to contact a single gene.
453 Further use of this approach will help to clarify hidden mechanisms of human disease
454 that are driven by genetic perturbations in non protein-coding DNA elements, which can
455 now be linked to their cognate gene targets in primary cells.

456

457 **ACKNOWLEDGEMENTS**

458

459 We thank members of the Chang and Greenleaf laboratories for helpful discussions and
460 Justin Tumey for artwork. This work was supported by National Institutes of Health
461 (NIH) P50HG007735 (H.Y.C. and W.J.G.) and U19AI057266 (W.J.G.), Human Frontier
462 Science Program (W.J.G.), Rita Allen Foundation (W.J.G.), and the Scleroderma
463 Research Foundation (H.Y.C.). M.R.M. and E.A.B. acknowledge support from the
464 National Science Foundation Graduate Research Fellowship. A.T.S. is a Cancer
465 Research Institute Irvington Fellow supported by the Cancer Research Institute. B.G.G.
466 was supported by an IGI-AstraZeneca Postdoctoral Fellowship. M.R.C. is supported by
467 a grant from The Leukemia & Lymphoma Society Career Development Program. J.E.C.
468 was supported by the Li Ka Shing Foundation and the Heritage Medical Research
469 Institute. W.J.G. and A.M. are Chan Zuckerberg Biohub investigators. A.M. serves as an
470 advisor to Juno Therapeutics and PACT Therapeutics and the Marson lab has received
471 sponsored research support from Juno Therapeutics and Epinomics. A.M. and J.E.C.
472 are founders of Spotlight Therapeutics. Sequencing was performed by the Stanford
473 Functional Genomics Facility (NIH S10OD018220). We thank Agilent Technologies for
474 generating oligo pools for cloning of the CRISPRa gRNAs. We thank the UC Berkeley
475 High Throughput Screening Facility and Flow Cytometry Facility. H.Y.C. and W.J.G. are
476 founders of Epinomics and members of its scientific advisory board.

477

478 **AUTHOR CONTRIBUTIONS**

479

480 M.R.M., A.T.S., W.J.G., and H.Y.C. conceived the project. M.R.M., A.T.S., J.T., and R.L.
481 performed all genomics assays with help from T.N., M.R.C., N.S., and R.A.F. A.T.S.
482 performed all sorting for experiments. B.G.G., S.W.C., M.R.M., M.L.N., K.R.K., and
483 D.R.S., performed all CRISPR validation experiments. E.A.B., C.D., M.R.M., and J.X.

484 analyzed HiChIP data. J.G., A.T.S., and Y.W. analyzed ATAC-seq data. A.J.R. and
485 P.G.G. analyzed GWAS SNPs in HiChIP data. A.K., P.A.K., A.M., J.E.C., T.Q., W.J.G.,
486 and H.Y.C guided experiments and data analysis. M.R.M, A.T.S, E.A.B, C.D., W.J.G,
487 and H.Y.C. wrote the manuscript with input from all authors.
488
489

490 **MAIN TEXT REFERENCES**

491

492 1. Dixon, J. R. *et al.* Topological domains in mammalian genomes identified by analysis of
493 chromatin interactions. *Nature* **485**, 376–380 (2012).

494 2. van Arensbergen, J., van Steensel, B. & Bussemaker, H. J. In search of the determinants of
495 enhancer-promoter interaction specificity. *Trends Cell Biol.* **24**, 695–702 (2014).

496 3. Lieberman-Aiden, E. *et al.* Comprehensive mapping of long-range interactions reveals
497 folding principles of the human genome. *Science* **326**, 289–293 (2009).

498 4. Rao, S. S. P. *et al.* A 3D map of the human genome at kilobase resolution reveals
499 principles of chromatin looping. *Cell* **159**, 1665–1680 (2014).

500 5. Fulco, C. P. *et al.* Systematic mapping of functional enhancer-promoter connections with
501 CRISPR interference. *Science* aag2445 (2016). doi:10.1126/science.aag2445

502 6. Altshuler, D., Daly, M. J. & Lander, E. S. Genetic mapping in human disease. *Science* **322**,
503 881–888 (2008).

504 7. Kumar, V. *et al.* Human Disease-Associated Genetic Variation Impacts Large Intergenic
505 Non-Coding RNA Expression. *PLOS Genet.* **9**, e1003201 (2013).

506 8. Edwards, S. L., Beesley, J., French, J. D. & Dunning, A. M. Beyond GWASs: Illuminating the
507 Dark Road from Association to Function. *Am. J. Hum. Genet.* **93**, 779–797 (2013).

508 9. Welter, D. *et al.* The NHGRI GWAS Catalog, a curated resource of SNP-trait associations.
509 *Nucleic Acids Res.* **42**, D1001–D1006 (2014).

510 10. Smemo, S. *et al.* Obesity-associated variants within FTO form long-range functional
511 connections with IRX3. *Nature* **507**, 371–375 (2014).

512 11. Claussnitzer, M. *et al.* FTO Obesity Variant Circuitry and Adipocyte Browning in
513 Humans. *N. Engl. J. Med.* **373**, 895–907 (2015).

514 12. Grubert, F. *et al.* Genetic Control of Chromatin States in Humans Involves Local and
515 Distal Chromosomal Interactions. *Cell* **162**, 1051–1065 (2015).

516 13. Mifsud, B. *et al.* Mapping long-range promoter contacts in human cells with high-
517 resolution capture Hi-C. *Nat. Genet.* **47**, 598–606 (2015).

518 14. Javierre, B. M. *et al.* Lineage-Specific Genome Architecture Links Enhancers and Non-
519 coding Disease Variants to Target Gene Promoters. *Cell* **167**, 1369–1384.e19 (2016).

520 15. Sanjana, N. E. *et al.* High-resolution interrogation of functional elements in the
521 noncoding genome. *Science* **353**, 1545–1549 (2016).

522 16. Mumbach, M. R. *et al.* HiChIP: efficient and sensitive analysis of protein-directed
523 genome architecture. *Nat. Methods* **advance online publication**, (2016).

524 17. Heintzman, N. D. *et al.* Distinct and predictive chromatin signatures of
525 transcriptional promoters and enhancers in the human genome. *Nat. Genet.* **39**, 311–318
526 (2007).

527 18. Creyghton, M. P. *et al.* Histone H3K27ac separates active from poised enhancers and
528 predicts developmental state. *Proc. Natl. Acad. Sci. U. S. A.* **107**, 21931–21936 (2010).

529 19. Rada-Iglesias, A. *et al.* A unique chromatin signature uncovers early developmental
530 enhancers in humans. *Nature* **470**, 279–283 (2011).

531 20. Ferraro, A. *et al.* Interindividual variation in human T regulatory cells. *Proc. Natl.*
532 *Acad. Sci. U. S. A.* **111**, E1111-1120 (2014).

533 21. Arvey, A. *et al.* Genetic and epigenetic variation in the lineage specification of
534 regulatory T cells. *eLife* **4**, e07571 (2015).

535 22. Bettelli, E. *et al.* Reciprocal developmental pathways for the generation of
536 pathogenic effector TH17 and regulatory T cells. *Nature* **441**, 235–238 (2006).

537 23. Acosta-Rodriguez, E. V. *et al.* Surface phenotype and antigenic specificity of human
538 interleukin 17-producing T helper memory cells. *Nat. Immunol.* **8**, 639–646 (2007).

539 24. Morita, R. *et al.* Human blood CXCR5(+)CD4(+) T cells are counterparts of T
540 follicular cells and contain specific subsets that differentially support antibody secretion.
541 *Immunity* **34**, 108–121 (2011).

542 25. Farh, K. K.-H. *et al.* Genetic and epigenetic fine mapping of causal autoimmune
543 disease variants. *Nature* **518**, 337–343 (2015).

544 26. Simeonov, D. R. *et al.* Discovery of an autoimmunity-associated IL2RA enhancer by
545 unbiased targeting of transcriptional activation. *bioRxiv* 091843 (2016).
546 doi:10.1101/091843

547 27. Engreitz, J. M. *et al.* Local regulation of gene expression by lncRNA promoters,
548 transcription and splicing. *Nature* **539**, 452–455 (2016).

549 28. Dao, L. T. M. *et al.* Genome-wide characterization of mammalian promoters with
550 distal enhancer functions. *Nat. Genet.* **49**, 1073–1081 (2017).

551 29. Ernst, J. & Kellis, M. ChromHMM: automating chromatin-state discovery and
552 characterization. *Nat. Methods* **9**, 215–216 (2012).

553 30. Sanborn, A. L. *et al.* Chromatin extrusion explains key features of loop and domain
554 formation in wild-type and engineered genomes. *Proc. Natl. Acad. Sci. U. S. A.* **112**,
555 E6456-6465 (2015).

556 31. Li, G. *et al.* Extensive promoter-centered chromatin interactions provide a
557 topological basis for transcription regulation. *Cell* **148**, 84–98 (2012).

558 32. Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y. & Greenleaf, W. J. Transposition
559 of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-
560 binding proteins and nucleosome position. *Nat. Methods* **10**, 1213–1218 (2013).

561 33. Samstein, R. M. *et al.* Foxp3 exploits a pre-existent enhancer landscape for
562 regulatory T cell lineage specification. *Cell* **151**, 153–166 (2012).

563 34. Ye, C. J. *et al.* Intersection of population variation and autoimmunity genetics in
564 human T cell activation. *Science* **345**, 1254665 (2014).

565 35. Petukhova, L. *et al.* Genome-wide association study in alopecia areata implicates
566 both innate and adaptive immunity. *Nature* **466**, 113–117 (2010).

567 36. Raj, T. *et al.* Polarization of the effects of autoimmune and neurodegenerative risk
568 alleles in leukocytes. *Science* **344**, 519–523 (2014).

569 37. Schiering, C. *et al.* The alarmin IL-33 promotes regulatory T-cell function in the
570 intestine. *Nature* **513**, 564–568 (2014).

571 38. Huang, H. *et al.* Fine-mapping inflammatory bowel disease loci to single-variant
572 resolution. *Nature* (2017). doi:10.1038/nature22969

573 39. Onengut-Gumuscu, S. *et al.* Fine mapping of type 1 diabetes susceptibility loci and
574 evidence for colocalization of causal variants with lymphoid gene enhancers. *Nat. Genet.*
575 **47**, 381–386 (2015).

576 40. O’Shea, J. J., Lahesmaa, R., Vahedi, G., Laurence, A. & Kanno, Y. Genomic views of
577 STAT function in CD4+ T helper cell differentiation. *Nat. Rev. Immunol.* **11**, 239–250
578 (2011).

579 41. Miller, C. L. *et al.* Integrative functional genomics identifies regulatory mechanisms
580 at coronary artery disease loci. *Nat. Commun.* **7**, 12092 (2016).

581 42. Nurnberg, S. T. *et al.* Coronary Artery Disease Associated Transcription Factor
582 TCF21 Regulates Smooth Muscle Precursor Cells That Contribute to the Fibrous Cap.
583 *PLoS Genet.* **11**, e1005155 (2015).

584 43. McPherson, R. *et al.* A common allele on chromosome 9 associated with coronary
585 heart disease. *Science* **316**, 1488–1491 (2007).

586 44. Helgadottir, A. *et al.* A common variant on chromosome 9p21 affects the risk of
587 myocardial infarction. *Science* **316**, 1491–1493 (2007).

588 45. Clarke, R. *et al.* Genetic variants associated with Lp(a) lipoprotein level and coronary
589 disease. *N. Engl. J. Med.* **361**, 2518–2528 (2009).

590 46. CARDIoGRAMplusC4D Consortium *et al.* Large-scale association analysis identifies
591 new risk loci for coronary artery disease. *Nat. Genet.* **45**, 25–33 (2013).

592 47. Leung, D. *et al.* Integrative analysis of haplotype-resolved epigenomes across human
593 tissues. *Nature* **518**, 350–354 (2015).

594 48. Dixon, J. R. *et al.* Chromatin architecture reorganization during stem cell
595 differentiation. *Nature* **518**, 331–336 (2015).

596 49. Franzén, O. *et al.* Cardiometabolic risk loci share downstream cis- and trans-gene
597 regulation across tissues and diseases. *Science* **353**, 827–830 (2016).

598
599
600
601
602
603
604
605
606
607
608

609 **FIGURE LEGENDS**

610
611 **Fig. 1 HiChIP identifies high-resolution chromosome conformation in primary**
612 **human T cells. (A)** Primary T cell H3K27ac HiChIP experimental outline. **(B)** (Left)
613 FACS strategy for Naïve, T_{H17}, and T_{reg} cells from total peripheral blood CD4⁺ T cells.
614 Number represents percent of total CD4⁺ T cells within that gate. (Right) Knight-Ruiz
615 (KR) matrix-balanced interaction maps for Naïve, T_{H17}, and T_{reg} cells at 500 kb, 25 kb,
616 and 5 kb resolution, and raw interaction maps at 1 kb resolution, centered on the *KLF2*,
617 *RBPJ*, and *LRRC32* loci. **(C)** HiChIP 1D and 3D signal enrichment at the *RORC* locus in
618 T_{H17} over Naïve T cells.
619

620
621 **Fig. 2 Validation of regulatory elements identified by H3K27ac HiChIP with**
622 **CRISPR interference and activation. (A)** Interaction profile of the *MYC* promoter in
623 K562 H3K27ac HiChIP at 10 kb resolution. K562 H3K27ac ChIP-Seq is from ENCODE.
624 CRISPRi-validated regulatory regions in K562 cells are indicated⁵. **(B)** Interaction profile
625 of the *GATA1* promoter in K562 H3K27ac HiChIP at 1 kb resolution. CRISPRi-validated
626 regulatory regions in K562 cells are indicated⁵. **(C)** Correlation of *MYC* K562 H3K27ac
627 HiChIP signal with max CRISPRi score within the HiChIP 10 kb window. **(D)** Interaction
628 profiles of the *MYC* promoter in GM12878 and My-La H3K27ac HiChIP at 10 kb
629 resolution. T cell H3K27ac ChIP-seq and ATAC-seq are from Naïve T cells. **(E)** (Top)
630 CRISPRi validation in GM12878 cells of GM12878 and My-La-biased *MYC* enhancers.
631 (Bottom) *MYC* RNA levels by qRT-PCR and cell growth rates in CRISPRi GM12878
632 cells targeted to cell type-biased enhancers, the *MYC* promoter, and a non-targeting
633 negative control (n = 3). * corresponds to p-value < 0.05, ** to p-value < 0.01, *** to p-
634 value < 0.001, **** to p-value < 0.0001, and n.s. to not significant. The box extends from
635 the 25th to 75th percentiles with a line representing the median, and the whiskers go the
636 minimum and maximum values. **(F)** Interaction profile of the *CD69* promoter in Jurkat
637 H3K27ac HiChIP at 5 kb and 1 kb resolutions. The 1 kb profile is focused on the window
638 of the CRISPRa tiling screen. CRISPRa-validated regulatory regions in Jurkat cells are
639 indicated²⁶. **(G)** (Top) CRISPRa validation in Jurkat cells of *CD69* distal enhancers.
640 (Bottom) *CD69* RNA and protein levels in CRISPRa Jurkat cells targeted to distal
641 enhancers, the *CD69* promoter, the *KLRF2* promoter as a locus negative control, and a
642 non-targeting negative control (n = 2).
643

644 **Fig. 3 Dynamic 3D enhancer landscapes in T cell differentiation. (A)**
645 Conformational features observed by H3K27ac HiChIP. **(B)** HiChIP EIS in 913
646 differential interactions identified in T cell subtypes. Interactions are clustered by cell-
647 type specificity. **(C)** Cell-type specific motif identification from ATAC-seq peaks in biased
648 EIS anchors. **(D)** EIS bias quartiles for Naïve to T_{H17} and Naïve to T_{reg} differentiation,
649 with corresponding differential RNA gene expression rankings. **(E)** Proportion of ATAC-
650 seq peaks within HiChIP differential interaction anchors that are cell-type specific (\log_2
651 fold change > 1) or shared across all three subtypes. **(F)** Interaction profile of the
652 *BACH2* promoter at 5 kb resolution, demonstrating shared accessibility signal at Naïve-

652 biased EIS. **(G)** Global correlation of EIS and ATAC-seq fold-change in different T cell
653 subset pairwise comparisons.
654

655 **Fig. 4 HiChIP identifies cell type-specificity and target genes of autoimmune**
656 **diseases variants.** **(A)** Generation of a loop set between all autoimmune SNPs and
657 gene promoters within a 1 Mb region. **(B)** H3K27ac ChIP and HiChIP signal bias in T
658 cell subtypes for SNP-TSS pairs. For each bin, PICS SNPs are tagged by H3K27ac only
659 in the concordant cell type for the bias tested. SNPs are grossly divided into
660 associations with autoimmune diseases or control, non-immune traits. **(C)** EIS Bias of
661 SNP-TSS loops (with nearest gene annotated) in T_{H17} and T_{reg} subsets versus Naïve,
662 and T_{H17} versus T_{reg} . **(D)** Number of HiChIP gene targets versus nearest gene
663 predictions for all looping nongenic autoimmune SNPs as well as SNPs for specific
664 diseases. **(E)** Global validation of HiChIP SNP gene targets. Synthetic SNP-TSS pairs
665 were generated from each CD4 $^{+}$ eQTL SNP to its associated gene and compared to
666 both a distance-matched shuffled SNP-TSS pair and a liver eQTL SNP-TSS pair. **(F)**
667 HiChIP target gene RNA levels by qRT-PCR in CRISPRi My-La cells targeted to SNP-
668 containing enhancers of interest, as well as positive control sgRNAs to the HiChIP
669 target promoters and a non-targeting negative control ($n = 3$). * corresponds to p-value
670 < 0.05 , ** to p-value < 0.01 , *** to p-value < 0.001 , **** to p-value < 0.0001 , and n.s. to
671 not significant. The box extends from the 25th to 75th percentiles with a line representing
672 the median, and the whiskers go the minimum and maximum values.
673

674 **Fig. 5 Fine-mapping of GWAS variants using H3K27ac HiChIP.** **(A)** Global validation
675 of HiChIP signal at putatively causal SNPs versus corresponding SNPs in LD ($r^2 \geq 0.8$)
676 for T_{H17} cells. SNP-TSS pairs were generated from published fine-mapped datasets,
677 compared to a distance-matched SNP-TSS pair set in the same LD block. **(B)**
678 Interaction profile of the *PTGER4* promoter, and a 1 kb resolution visualization of the
679 SNP-containing enhancer of interest. LD SNPs ($r^2 \geq 0.8$) correspond to GRASP SNPs
680 (genome-wide significance p-value $< 10^{-8}$). The highlighted SNP was identified in both
681 the high confidence PICS and GRASP datasets. **(C)** Interaction profiles of the *STAT1*
682 and *STAT4* promoters, with 1 kb resolution visualizations of the SNP-containing
683 enhancers of interest. Highlighted are 1D signal contributions at the *STAT1* and *STAT4*
684 promoters. Highlighted SNPs are PICS closest to focal EIS to *STAT4*.
685

686 **Fig. 6 HiChIP identifies allelic bias to target genes for cardiovascular disease risk**
687 **variants.** **(A)** Interaction profile of the *TCF21* gene promoter for H3K27ac HiChIP of
688 HCASMC and Naïve T cells. **(B)** EIS bias between HCASMC and Naïve T cells in a
689 union set of CARDIoGRAMplusC4D CAD and PICS autoimmune SNP-TSS loops. **(C)**
690 Q-Q plot of allelic EIS imbalance in high confidence loops. Allelic mapping biased loops
691 were identified through simulation and removed prior to EIS analysis. **(D)** EIS bias
692 between CAD risk variants and their alternative alleles to eQTL associated target genes.
693 **(E)** Allele-specific HiChIP interaction profiles at the 9p21.3 and *SMAD3* loci at 10 kb
694 resolution in order to examine the functional consequence of a risk variant compared to
695 its alternative allele.
696

697 **METHODS**

698

699 **Human Subjects**

700 This study was approved by the Stanford University Administrative Panels on Human
701 Subjects in Medical Research, and written informed consent was obtained from all
702 participants.

703

704 **Cell Culture and Primary T cell Isolation**

705 Mouse ES cells (v6.5, Novus Biologicals: NBP1-41162) were cultured in Knockout
706 DMEM (Gibco) + 15% FBS and leukemia inhibitory factor (LIF, Millipore) to 80%
707 confluence. GM12878 (Coriell), Jurkat, and My-La (CD4⁺) cells (ATCC) were grown in
708 RPMI 1640 (Gibco) with 15% FBS to a concentration of 500,000 to 1 million cells per
709 mL. Normal donor human peripheral blood cells were obtained fresh from AllCells. CD4⁺
710 T cells were enriched from peripheral blood using the RosetteSep Human CD4⁺ T Cell
711 Enrichment Cocktail (StemCell Technology). For CD4⁺ T helper cell subtypes, Naïve T
712 cells were sorted as CD4⁺CD25⁻CD45RA⁺, T_H17 cells were sorted as CD4⁺CD25⁻
713 CD45RA⁻CCR6⁺CXCR5⁺, and T_{reg} cells were sorted as CD4⁺CD25⁺CD127^{lo}. Antibodies
714 used for FACS included: PerCP/Cy5.5 anti-CD45RA (Biolegend 304122), Brilliant Violet
715 510 anti-CD127 (Biolegend 351331), APC/Cy7 anti-CD4 (Biolegend 344616), PE anti-
716 CCR6 (Biolegend 353410), FITC anti-CD25 (Biolegend 302603), Brilliant Violet 421
717 anti-CXCR3 (Biolegend 353715), and BB515 anti-CXCR5 (BD Biosciences 564625).
718 For HiChIP experiments, 500,000 - 1 million cells were sorted into RPMI + 10% FCS.
719 For ATAC-seq experiments, 55,000 cells were sorted into RPMI + 10% FCS. Post-sort
720 purities of > 95% were confirmed by flow cytometry for each sample.

721

722 Primary human coronary artery smooth muscle cell (HCASMC) line derived from a
723 normal human donor heart was purchased from Cell Applications, Inc. (350-05A) and
724 cultured in smooth muscle growth medium (Lonza, CC-3182) supplemented with hEGF,
725 insulin, hFGF-b, and 5% FBS. Cells were grown according to Lonza's instructions.

726

727 **Cell Fixation**

728 Detached cell lines or sorted CD4⁺ T cells were pelleted and resuspended in fresh 1%
729 formaldehyde (Thermo Fisher) at a volume of 1 mL formaldehyde for 1 million cells.
730 Cells were incubated at room temperature for 10 min with rotation. Glycine was added
731 at a final concentration of 125mM to quench the formaldehyde, and cells were incubated
732 at room temperature for 5 min with rotation. Finally, cells were pelleted and washed with
733 PBS, pelleted again, and stored at -80 °C or immediately taken into the HiChIP
734 protocol.

735

736 **HiChIP**

737 The HiChIP protocol was performed as previously described, using either H3K27ac
738 antibody (Abcam ab4729) or CTCF (Abcam ab70303)¹⁶ with the following modifications.
739 For primary T cells, we performed HiChIP on as many cells as we could obtain from a
740 blood donation - approximately 500,000 - 1 million cells per T cell subtype per replicate.

741 We performed two minutes of sonication, no Protein A bead preclearing, used 4 µg of
742 H3K27ac antibody (Abcam ab4729), and captured the chromatin-antibody complex with
743 34 µL of Protein A beads (Thermo Fisher). Qubit quantification post ChIP ranged from 5
744 – 25 ng depending on the cell type and amount of starting material. The amount of Tn5
745 used and PCR cycles performed were based on the post ChIP Qubit amounts, as
746 previously described¹⁶.

747
748 25m cell line libraries were generated as previously described¹⁶. For low cell number
749 mouse embryonic stem cell samples, we performed two minutes of sonication and no
750 Protein A bead preclearing. Either 4 µg or 2µg of H3K27ac antibody (Abcam ab4729)
751 was used for ChIP in 500k or 100k/50k cells, respectively, and the chromatin-antibody
752 complex was captured with 34 (500k cells) or 20 µL (100k/50k cells) of Protein A beads.
753 Post-ChIP Qubit quantification for the 25m cell samples was approximately 1.5 µg. For
754 lower cell numbers, quantification was 30, 10, and 5 ng for 500k, 100k, and 50k cells,
755 respectively. The amount of Tn5 used and PCR cycles performed were based on the
756 post ChIP Qubit amounts, as previously described.

757
758 HiChIP samples were size selected by PAGE purification (300-700 bp) for effective
759 paired-end tag mapping, and therefore were removed of all primer contamination which
760 would contribute to recently reported "index switching" on the Illumina HiSeq 4000
761 sequencer⁵⁰. All libraries were sequenced on the Illumina HiSeq 4000 to an average
762 depth of 500-600M total reads.

763
764 **HiChIP Data Processing**
765 HiChIP paired-end reads were aligned to hg19 or mm9 genomes using the HiC-Pro
766 pipeline⁵¹. Default settings were used to remove duplicate reads, assign reads to MboI
767 restriction fragments, filter for valid interactions, and generate binned interaction
768 matrices. HiC-Pro filtered reads were then processed into a .hic file using the
769 hicpro2juicebox function. The Juicer pipeline HiCCUPS tool was used to identify high
770 confidence loops⁴ using the same parameters as for the GM12878 *in situ* Hi-C map:
771 hiccups -m 500 -r 5000,10000 -f 0.1,0.1 -p 4,2 -i 7,5 -d 20000,20000 .hic_input
772 HiCCUPS_output. For T cell Juicer loops, performing the default Juicer calls resulted in
773 a high rate of false positives upon visual inspection of the interaction matrix. We
774 therefore called loops with the same HiCCUPS parameters in two biological replicates
775 for each T cell subtype and then filtered loops for those that were reproducibly called in
776 both replicates. In addition, we removed all loops greater than 1 Mb.

777
778 1D signal enrichment and peak calling were generated from the HiC-Pro filtered
779 contacts file. Intrachromosomal contacts were filtered and both anchors were extended
780 by 75 base pairs. The combined bed file containing both anchors was then used to
781 generate bigwigs for visualization in the WashU Epigenome Browser or call peaks using
782 MACS2.

783

784 Allele-specific HiChIP data processing was achieved using HiC-Pro's allele-specific
785 analysis features⁵¹. First, HCASMC phasing data⁴¹ was used to mask the hg19 genome
786 and make indexes. HiC-Pro settings were similar as to described above, with the
787 exception that reads were aligned to the masked genome, and then assigned to a
788 specific allele based on phasing data.

789

790 **Interaction Matrices and Virtual 4C Visualization**

791 HiChIP interaction maps were generated with Juicebox using Knight-Ruiz (KR) matrix
792 balancing and visualized using Juicebox software at 500 kb, 25 kb, 10 kb, and 5 kb
793 resolutions as indicated in each analysis⁴. For 1 kb profiles, raw matrix counts were
794 visualized in Java TreeView.

795

796 Virtual 4C plots were generated from dumped matrices generated with Juicebox. The
797 Juicebox tools dump command was used to extract the chromosome of interest from the
798 .hic file. The interaction profile of a specific 5 kb or 10 kb bin containing the anchor was
799 then plotted in R. Replicate reproducibility was visualized with the mean profile shown
800 as a line and the shading surrounding the mean representing the standard deviation
801 between replicates. For the HCASMC data we observed low read coverage for allele-
802 specific v4Cs at loci of interest. This is due to the density of SNPs for this genotype, and
803 a low number of reads containing a phased SNP. We therefore could not observe
804 interaction profiles when visualizing separate replicates with the standard deviation. We
805 therefore utilized pseudoreplicates for the HCASMC v4C visualizations⁵².

806

807 High confidence Juicer loop calls were loaded into the WashU Epigenome Browser
808 along with corresponding ATAC-seq profiles and publically available H3K27ac ChIP-seq
809 data from the Roadmap Epigenome Project. Browser shots from WashU track sessions
810 were then included in virtual 4C and interaction map anecdotes.

811

812 **Reproducibility Scatter Plots and Correlations**

813 Biological and technical reproducibility comparisons between HiChIP experiments were
814 generated by counting reads supporting a set of Juicer loop calls. For biological
815 replicate comparisons, the loop set called from the merged replicates was used. For the
816 comparison in mES cells between low cell number and 25 million cells, the union loop
817 set between the two maps was used. The Pearson correlation between replicates or
818 experiments was calculated from depth-normalized reads using the cor() function in R.
819 Scatter plots were plotted using log-transformed raw reads supporting each loop.

820

821 **Promoter/Enhancer Annotations of HiChIP Loops**

822 Promoters were defined as 1 kb regions centered at the TSS, and enhancers were
823 identified as chromHMM enhancers not overlapping with promoters in any cell type. We
824 annotated loop anchors as 'other' if the anchor did not contain a promoter or enhancer
825 as defined above.

826

827 **Differential Analysis of HiCCUPS Loop Calls**

828 Juicer loop calls from the three T cell subtypes were initially combined into a union set
829 of T cell loops. Loop signal was then obtained for the biological replicates of each T cell
830 subtype. Vanilla coverage square root (VCsqrt) normalized signal for the interaction
831 matrix of each biological replicate using the Juicebox tools dump command. Normalized
832 signal was then assigned to the union loop set in each replicate.
833

834 VCsqrt signal per sample was quantile-quantile normalized under the assumption that
835 overall signal was identically distributed across all samples. Following normalization,
836 samples for Naïve, T_{H17} and T_{reg} cells shared Pearson correlations of 0.938, 0.942 and
837 0.934, respectively. PCA was performed using the prcomp function in R, which
838 demonstrated that the first PC, which exhibited near-identical loadings across the six
839 samples, explained 93% of the variance across the six samples. This was taken to
840 represent the shared signal across cell types. PCs 2-4 explained 2.2%, 2.0% and 1.4%,
841 respectively.
842

843 To study cell type-specific looping, the residual signal per loop was taken after
844 projecting the loop onto the unit vector along the diagonal (equal signal per cell type).
845 Cell type-specific and differential looping analysis were performed with the top and
846 bottom 5% of the distributions of either residual signal or differences between cell type
847 residual signals. Hierarchical clustering was performed using the union of all differential
848 loops in these extremes and using 1 minus the Pearson correlation as the distance
849 metric. QQ plots were generated by permuting residuals from the same cell type or
850 individual and summing them together and using this distribution to calculate p values
851 for the observed sums.
852

853 In parallel, differential loops were called using edgeR for both the mES and T cell
854 datasets. Again, biological replicate loop signal was obtained across a union set of
855 Juicer loops. We then used edgeR to identify loops with significant changes in signal
856 among pair-wise comparisons (FDR < 0.1, log₂FC > 1). Importantly, inspection of
857 differential loops identified from the two methods revealed high concordance.
858

859 Gene density was calculated from Ensembl gene annotations. GC content was
860 calculated per 10 kb bin using the bedtools nuc function and aggregated as needed.
861 Notably, Spearman correlation between gene density of an entire chromosome and the
862 number of differential loop anchors (rho = 0.914) was much higher than the correlations
863 between the variance in cell type signal per loop anchor and number of genes per 10 kb
864 window (rho = 0.322) and between differential loop anchors and gene density per 100
865 kb section (rho = 0.083). Correlations between GC content and number of differential
866 loops were similar at both the chromosome (rho = 0.729) and 100 kb bin (rho = 0.148)
867 levels, but while local GC content is likely to confound relative abundance, it is unclear
868 how chromosome-wide GC content could have the same effect.
869

870 For mES analysis of H3K27ac- and cohesin-mediated HiChIP, we performed edgeR to
871 obtain the biased loops for each factor. To determine functional bias of the top loops,

872 overlap was determined between edgeR differential loop anchors and relevant ChIP-seq
873 peaks. Smc1a ChIP-seq peaks were obtained from a published dataset⁵³. CTCF, RNA
874 Polymerase II, and H3K27ac ChIP-seq peaks were obtained from the mouse ENCODE
875 repository⁵⁴.

876

877 **RNA Expression Analysis**

878 Previously generated RNA-seq data⁵⁵ from Naïve, T_H17 and T_{reg} cells was downloaded
879 as fastqs from ArrayExpress. Illumina adaptors were trimmed using CutAdapt and
880 Ensembl's cDNA transcripts were quantified using kallisto. Sleuth was used to identify
881 transcripts that were differentially expressed across cell types with FDR controlled at
882 5%. The mean TPM was calculated per cell type, and TSS differential looping quantiles
883 at genes with nonzero expression were correlated with differential expression
884 quantiles of the same genes. Only 10 kb segments of the genome that contained a
885 single annotated gene were considered to avoid errors in attribution of looping signal
886 per 10 kb bin. For genes with multiple annotated TSSs the 10 kb bin corresponding to
887 the median TSS was used. Significance was assessed by the cor.test function in R.

888

889 **Comparing HiChIP to Hi-C, ATAC-seq, ChIP-seq, and Capture-C datasets**

890 T cell subset ChIP-seq data was obtained from the WashU Roadmap repository. A
891 union set of peaks were called using MACS2 and peaks were quantified using Bedtools
892 intersect. Normalization for ChIP was performed using quantile normalization using
893 “preprocessCore” package in R.

894

895 Differential EIS was determined using TMM normalization in the “edgeR” package in R.
896 The significantly differential EIS (\log_2 fold-change > 1 and FDR < 10%) were determined
897 for each pairwise comparison. For each differential EIS, the maximum ATAC/ChIP
898 signal peak was assessed in each 10 kb anchor (to bias against low signal peaks) and
899 then the maximum \log_2 fold-change was compared to the differential EIS.

900

901 Differential 1D HiChIP was determined using TMM normalization in the “edgeR”
902 package in R. The significantly differential 1D HiChIP in EIS 10 kb anchors (\log_2 fold-
903 change > 1 and FDR < 10%) were determined for each pairwise comparison. For each
904 differential 1D HiChIP anchor, the maximum ATAC/ChIP signal peak was assessed (to
905 bias against low signal peaks) and then the maximum \log_2 fold-change was compared
906 to the differential 1D HiChIP.

907

908 To determine if reference cell line Hi-C data with primary T cell H3K27ac ChIP-seq
909 could recapitulate EIS in primary T cells, GM Hi-C loop anchors were binned with
910 increasing T cell subset ChIP signal as well as GM H3K27ac ChIP-seq signal (Encode).
911 Loop overlap was then determined for the different H3K27ac ChIP signal bins with
912 HiChIP loops.

913

914 To compare directly with CD4⁺ Capture-C data, CHiCAGO loops were called in Naïve,
915 T_H17, and T_{reg} datasets. CHiCAGO calls were then combined into a union set, and loop

916 signal was obtained for the biological replicates of each T cell subtype using the
917 Juicebox tools dump command. We then used edgeR to identify loops with significant
918 changes in signal among pair-wise comparisons (FDR < 0.05). Total and differential
919 loops were then overlapped with CD4⁺ Capture-C CHiCAGO data.
920

921 **Calculation of Disease-specific GWAS SNP Enrichment in Loop Anchors**

922 We categorized GWAS SNPs into sets relevant to diseases of the immune system and,
923 separately, diseases with no known immune component²⁵. For each disease in the
924 immune or non-immune set, we determined the proportion of all GWAS SNPs
925 associated with that disease which overlap the positions of loop anchors based on a
926 union set of loops identified in Naïve, T_H17, and T_{reg} cells. The ratio of the proportion of
927 immune and non-immune overlaps relative to a shuffled control was reported as the
928 enrichment of immune GWAS SNPs.
929

930 **Distance-matched eQTL SNP-TSS Comparisons**

931 We obtained three groups of eQTL SNP-TSS pairs within 1 Mb distance for HiChIP EIS
932 comparisons. The treatment group contains CD4 eQTL-TSS targets. We have two
933 distance-matched groups as control. The first control group contains the CD4 eQTL
934 SNP-random TSS pairs such that the distance between eQTL SNP and random TSS
935 differs by at most 5 kb with the treatment group. The second control group contains liver
936 eQTL SNP-TSS targets that are also distance matched with the treatment group. The
937 random eQTL SNP-TSS pairs were generated by individual chromosome, such that
938 number of control pairs and treatment pairs are the same for every chromosome. In
939 total, there were 158,482 distance-matched eQTL-TSS pairs. We compared the 5 kb
940 resolution EIS among the three eQTL SNP-TSS groups for all three T cell subtypes.
941 Results show that in all the cases, the EIS between CD4 eQTL-TSS targets were
942 significantly higher than the two control groups (p-value < 10⁻¹⁶).
943

944 **Distance-matched Fine-mapped SNP-TSS Comparisons**

945 We obtained a list of putatively causal SNPs from the PICS SNP list²⁵ (PICS probability
946 > 0.5), as well as fine-mapped SNPs associated with inflammatory bowel disease
947 (IBD)³⁸ or Type 1 Diabetes (T1D)³⁹. Next, we obtained all SNPs in LD with each
948 putatively causal SNP using European linkage disequilibrium blocks determined by all
949 SNPs with an $r^2 \geq 0.8$ with the SNP being considered. For the fine-mapped (T1D/IBD)
950 sets, using SNPs in LD with highly significant GWAS SNPs may mean that there are
951 several SNPs of equal or greater significance in the control set, but we still expect an
952 enrichment relative to the LD block.
953

954 We collected all the synthetic pairs between the putatively causal immune-disease
955 related SNPs (IBD, T1D and PICS) and nearby genes within 300 kb distance. To
956 perform the distance-matched EIS comparisons, for each fine-mapped SNP category,
957 we selected the SNP-TSS control pairs which satisfy two constraints: (1) the selected
958 control SNP is positioned at least 5 kb away from the fine-mapped SNP in the same
959 linkage disequilibrium block; (2) the distance of SNP-TSS control pair differs with fine-

960 mapped SNP and the target gene at most 5 kb.

961

962 SNP-TSS Loop Analyses

963 We obtained 7,747 PICS SNPs that are associated with autoimmune disease or non-
964 immune traits²⁵. 4,331 (55.9%) were associated with autoimmune disease, and 3,416
965 (44.1%) were associated with non-immune traits. In addition we obtained a set of SNPs
966 associated with six overlapping autoimmune diseases using the GRASP catalog
967 (genome-wide significance p-value < 10⁻⁸).

968
969 We constructed a synthetic loop set for immune and non-immune SNPs and any TSS
970 within 1 Mb of each SNP. We then assigned VCsqrt signal in each biological replicate of
971 the three T cell subtypes to the synthetic loop set, as described above.

972
973 VCsqrt signal per sample was quantile-quantile normalized as above. In this analysis,
974 we did not restrict to HiCCUPS-identified loops but instead examined all possible
975 interactions between a SNP and TSS within 1 Mb. Many of these interactions do not
976 exist, and therefore had little or no matrix-balanced signal supporting them. While we
977 removed all SNP TSS pairs below an average of 1 normalized read per sample from
978 subsequent analyses, in general these false interactions contributed little to the overall
979 differential signal for a trait.

980
981 H3K27ac data was downloaded from the WashU Roadmap repository. PICS SNPs were
982 taken from Farh, et al²⁵. Rather than require strict membership within H3K27ac peaks,
983 PICS SNPs were labeled as active if they lied within 8 kb of a peak, raising the number
984 of nominally functional SNPs from ~700 to ~3200 per cell type, out of 7735 total
985 candidate SNPs.

986
987 Differential looping across cell types was assessed by one-sided t-test per trait and
988 activity partition if there were at least eight PICS SNP-TSS pairs in the partition. T_{H17}
989 bias was defined as T_{H17} total loop signal minus Naïve total loop signal; T_{reg} bias was
990 defined as T_{reg} total loop signal minus Naïve total loop signal; and Naïve bias was
991 defined as Naïve total loop signal minus one-half times T_{H17} and T_{reg} total loop signal.
992 For the main text figure, Naïve bias was assessed only using SNPs that were active in
993 Naïve cells, T_{H17} bias from SNPs active in T_{H17} and not Naïve, and T_{reg} bias from
994 SNPs active in T_{reg} and not Naïve. p-values were corrected for multiple hypothesis
995 testing by the Holm method using the p.adjust function in R. Bias assessed from SNPs
996 with the opposing cell type specificities (e.g. Naïve bias using SNPs active in T_{H17} and
997 T_{reg} but not Naïve) yielded no significant hits after correction.

998
999 **SNP and TSS Connectivity Analysis**

1000 Among all immune and non-immune SNPs, 2,562 (33.1%) were located within a 25 kb
1001 region centered around TSS, 2,618 (33.8%) were located in a gene body, and the
1002 remaining 2,567 (33.1%) were located in intergenic regions.

1003

1004 To capture the confident SNP-TSS connections for SNP-TSS pair identification, we
1005 overlapped the anchors of significant loops that were identified by Fit-Hi-C⁵⁶ with the
1006 SNP/TSS locations. We identified 14,738 SNP-TSS pairs that were supported by Fit-Hi-
1007 C loops, and there were 3,046 unique SNPs connected with at least one gene. Among
1008 those 3,046 SNPs, there were 2,181 (71.6%) and 865 (28.4%) SNPs annotated with
1009 immune and non-immune SNPs, respectively. As expected, the immune disease SNPs
1010 are more likely to connect with genes (Fisher's exact test, p-value = 4.8×10^{-85}).
1011

1012 **Phasing of HCASMC Samples**

1013 We used BEAGLE 4.1 to impute and phase recalibrated variants using 1000 Genome
1014 phase 3 version 5a as a reference panel. The Beagle phasing algorithm was set on the
1015 following criteria. At each iteration that the algorithm performs, phased input data are
1016 used to build a local model of a haplotype-cluster. After the local haplotype-cluster
1017 model is created, for each individual phased haplotypes are sampled using the induced
1018 diploid HMM conditional on the individual's genotypes. The sampled haplotypes are
1019 then used as the input to feed in the next iteration of the algorithm. In the final iteration,
1020 instead of sampling haplotypes, BEAGLE uses the Viterbi algorithm to
1021 select the conditional on the diploid HMM and the individual's genotype data and to
1022 obtain the haplotypes for each individual that possess the greatest probability, and
1023 these most-likely haplotypes are the final output of the BEAGLE phasing algorithm.
1024

1025 **Allelic Mapping Bias Simulation**

1026 We constructed a personal genome by editing the reference genome (hg19) according
1027 to SNP information. SNPs labeled as "1|0" or "1|1" in the vcf file were replaced with the
1028 alternative allele for genome 1. SNPs labeled as "0|1" or "1|1" in the vcf file were
1029 replaced with the alternative allele for genome 2. Loop anchors were extended 100 bp
1030 in both directions and sequences were extracted using samtools for each
1031 genome. ~20X reads were simulated for each region, using wgsim with parameters " -e
1032 0.01 -d 100 -s 20 -1 75 -2 75 -S -1 -h -R 0.1". Simulated reads were mapped to the
1033 "N" masked genome. Mapping parameters were the same used by HiC-Pro ("--very-
1034 sensitive -L 30 --score-min L, -0.6, -0.2 --end-to-end --reorder --phred33-quals). Allelic
1035 specific reads were separated according to the SNP information and then counted for
1036 each loop anchor using bedtools.
1037

1038 **Correction for False Positives**

1039 Despite not being originally implemented in enrichment interaction datasets, we have
1040 previously demonstrated that KR and VC matrix balancing corrects for false positives
1041 caused by high 1D fragment visibility¹⁶. Loop calls are either from HiCCUPS or Fit Hi-C,
1042 which are KR and VC matrix balanced, respectively. For differential analysis of
1043 HiCCUPS (Figure 3) and SNP-TSS Fit Hi-C (Figure 4c) loop calls, we are restricted
1044 within a set of loops that were obtained from matrix balancing. Therefore, while
1045 differential loops can be driven by both changes in looping strength and/or 1D ChIP
1046 signal, the final interactions being observed are loops. Additionally, we performed
1047 differential analysis of HiCCUPS loop calls using two separate methods – one using

1048 VCsqrt normalized reads and another with non-normalized reads (edgeR) and found
1049 high agreement. The SNP-TSS synthetic loop analysis in Figure 4b was not restricted to
1050 loop calls, however was performed with VCsqrt matrix balanced reads to avoid false
1051 positives. Those SNP-TSS synthetic loops were then subset by overlap with Fit Hi-C for
1052 further differential analyses in Figure 4c. Finally, virtual 4C analysis was performed on
1053 non-normalized reads to highlight EIS contributions of both 1D and 3D signal changes,
1054 however HiCCUPS loop calls are included in the relevant anecdotes.
1055

1056 **ATAC-seq**

1057 Cells were isolated and subjected to ATAC-seq as previously described¹⁶. Briefly,
1058 55,000 cells were pelleted, resuspended in 50 μ L lysis buffer (10mM Tris-HCl, pH 7.4,
1059 3mM MgCl₂, 10mM NaCl, 0.1% NP-40 (Igepal CA-630), and immediately centrifuged at
1060 500 rcf for 10 min at 4°C. The nuclei pellets were resuspended in 50 μ L transposition
1061 buffer (25 μ L 2X TD buffer, 22.5 μ L dH₂O, 2.5 μ L Illumina Tn5 transposase), and
1062 incubated at 37°C for 30 min. Transposed DNA was purified with MinElute PCR
1063 Purification Kit (Qiagen), and eluted in 10 μ L EB buffer.
1064

1065 **ATAC-seq Data Processing**

1066 Adapter sequence trimming using SeqPurge and mapping to hg19 using Bowtie2 were
1067 performed. These reads were then filtered for mitochondrial reads, low quality, and PCR
1068 duplicates. The filtered reads for each sample were merged and peak calling was
1069 performed by MACS2. Each individual sample reads in peaks were quantified using
1070 Bedtools intersect with the MACS2 narrow peaks. Peak counts were then combined into
1071 a matrix NxM where N represents called peaks and M represents the samples and each
1072 value Di,j represents the peak intensity for the respective peak i in sample j. This matrix
1073 was then normalized using the “CQN” package in R to minimize bias in GC content and
1074 length.
1075

1076 **CRISPRi Validation of HiChIP Targets**

1077 For virus production, 5×10^6 of HEK293T cells were plated per 10 cm plate. The
1078 following day, plasmid encoding lentivirus was co-transfected with pMD2.G and psPAX2
1079 into the cells using Lipofectamine 3000 (Thermo Fisher, L3000) according to the
1080 manufacturer’s instructions. Supernatant containing viral particles was collected 48
1081 hours after transfection and filtered. For lentivirus encoding individual sgRNAs, virus
1082 was concentrated 10-fold using Lenti-X concentrator (Clontech, 631232) and stored at -
1083 80°C.
1084

1085 In order to generate a My-La cell line expressing CRISPRi, 2×10^6 of My-La cells were
1086 plated per T75 flask. A dCas9-BFP-KRAB-2A-Blast construct was generated by
1087 inserting a 2A-Blast cassette into dCas9-BFP-KRAB (Addgene 46911). 24 hours after
1088 plating, lentivirus harboring the dCas9-KRAB construct was added with polybrene (4 μ g
1089 / mL). Media was changed 24 hours after infection, and then again 48 hours after
1090 infection with Blasticidin (Thermo Fisher, A1113903) at 4 μ g / mL. Blasticidin resistant
1091 cells were selected for eight days with changing media every other day.

1092

1093 Three different U6 were used for transcription of three different sgRNAs targeting the
1094 candidate enhancers, as previously described⁵⁷. For *MYC* locus CRISPRi experiments,
1095 each enhancer was targeted by one guide, and therefore all *MYC* GM or My-La
1096 enhancers together were targeted in one experiment. For the PICS SNP CRISPRi
1097 experiments, three guides were targeted to a single SNP-containing enhancer. One of
1098 three sgRNAs was cloned into a lentiviral vector with a human (pMJ117, Addgene
1099 85997), mouse (pMJ179, Addgene 85996) or bovine (pMJ114, Addgene 85995) U6
1100 promoter. These U6-sgRNA constructs were then combined into lentivirus with a
1101 Puromycin-2A-mCherry vector, which was modified from Addgene 46914. My-La-
1102 CRISPRi cells were infected with lentivirus harboring 3 sgRNAs and selected by
1103 Puromycin (Thermo Fisher, A11138) at a final concentration of 1 µg / mL. Previously
1104 reported sgRNAs targeting VPS54 or SEC24C were used for validating CRISPRi
1105 functionality in My-La cell line⁵⁸.

1106

1107 For readout of CRISPRi validation, we performed qRT-PCR and cell growth assays on
1108 three biological and two technical replicates. For qRT-PCR, RNA was Trizol extracted
1109 (Thermo Fisher, 15596026) and purified using the Zymo RNA Clean and Concentrator
1110 kit (Zymo Research, R1016). qRT-PCR was performed with Brilliant qRT-PCR
1111 mastermix (Agilent, 600825). Ct values were measured by using Lightcycler 480
1112 (Roche) and relative expression level was calculated by ddCt method compared to a
1113 *GAPDH* control. Primer sequences are listed in Supplementary Table 6. For cell growth,
1114 we used the CellTiter-Glo kit (Promega, G7572) according to the manufacturers
1115 instructions. Statistics for both RNA and cell growth changes were calculated using a
1116 Student's t test against the non-targeting control.

1117

1118 **CRISPRa Validation of HiChIP Targets**

1119 Jurkat cells were transduced with a lentiviral dCas9-VP64-2A-GFP expression vector
1120 (Addgene 61422). Single GFP+ cells were sorted by FACS into the wells of a 96-well
1121 plate, and a clone with bright uniform GFP expression were selected for use in future
1122 experiments.

1123

1124 sgRNAs were cloned in arrayed format for CD69 HiChIP peaks falling outside the range
1125 of the tiling CRISPRa screen²⁶. sgRNAs were chosen based on high predicted on-target
1126 activity⁵⁹ and low predicted off-target activity⁶⁰. sgRNAs were cloned into the lentiviral
1127 expression vector “pCRISPRa-v2” (Addgene 84832) as described in Horlbeck et al⁶¹.
1128 Lentivirus was produced by transfecting HEK293T with standard packaging vectors
1129 using *TransIT-LTI* Transfection Reagent (Mirus, MIR 2306). Media was changed 24
1130 hours post-transfection. Viral supernatant was harvested at 48 and 72 hr following
1131 transfection and immediately used for infection of Jurkat-dCas9-VP64 cells.

1132

1133 Jurkat-dCas9-VP64 cells were infected with lentiviral sgRNAs by resuspending cells in a
1134 1:1 mix of fresh media and lentiviral supernatant at a final concentration of 0.25×10^6
1135 cells/mL with 5 µg / mL polybrene. Cells were spinfected for 1 hour at 1000 rcf, 32 °C.

1136 The next day, half of the media was removed and replaced with fresh lentiviral
1137 supernatant, and the spinfection was repeated. The next day, the cells were
1138 resuspended in fresh media with 1.5 µg / mL puromycin and cultured for 2 days to
1139 remove uninfected cells. For readout of CRISPRa validation, we performed qRT-PCR
1140 and FACS on two biological and two technical replicates. RNA extraction and qRT-PCR
1141 was performed as described above. Expression of CD69 on infected cells (GFP+BFP+)
1142 was analyzed by flow cytometry with an Attune NxT flow cytometer (Life Technologies).
1143 Statistics for both RNA and protein level changes were calculated with a one-way
1144 ANOVA followed by a Dunnet's multiple comparisons test against the non-targeting
1145 control.

1146

1147

1148

1149

1150

1151

1152

1153

1154

1155

1156

1157

1158

1159

1160

1161

1162

1163

1164

1165

1166

1167

1168

1169

1170

1171

1172

1173

1174

1175

1176

1177

1178

1179

1180 **SUPPLEMENTARY LEGENDS**

1181

1182 **Supplementary Figure 1. H3K27ac HiChIP enriches E-P-associated chromatin**
1183 **contacts. (A)** Schematic of chromatin contacts captured in H3K27ac HiChIP. **(B)** Loop
1184 call overlap for cohesin HiChIP and H3K27ac HiChIP in mES cells. **(C)** Contact distance
1185 distribution for loops that are biased in cohesin versus H3K27ac HiChIP. **(D)** Proportion
1186 of cohesin and H3K27ac biased HiChIP loops that have cohesin, CTCF, H3K27ac, and
1187 RNA polymerase II binding in at least one loop anchor. **(E)** Virtual 4C interaction profile
1188 of an H3K27ac-biased loop focused at the *MALAT1* promoter. **(F)** Virtual 4C interaction
1189 profile of a cohesin-biased loop with associated low transcriptional activity.

1190

1191 **Supplementary Figure 2. H3K27ac HiChIP achieves high chromatin loop signal-**
1192 **over-background at low cell inputs. (A)** KR balanced interaction matrices focused
1193 around the *Etv5* locus in mES cells with decreasing cellular starting material. **(B)** Read
1194 support reproducibility of loops in H3K27ac HiChIP libraries from 25 million cells
1195 compared to HiChIP in lower cell input libraries. **(C)** Aggregate peak analysis of loops in
1196 mES H3K27ac HiChIP libraries.

1197

1198 **Supplementary Figure 3. H3K27ac HiChIP generates reproducible chromatin loop**
1199 **signals at low cell inputs. (A)** Comparison of KR balanced interaction maps in
1200 H3K27ac HiChIP biological replicates. **(B)** Read support reproducibility of loops
1201 between H3K27ac HiChIP biological replicates. **(C)** HiCCUPS loop call overlap between
1202 H3K27ac HiChIP libraries from 25 million and 50 thousand mES cells. **(D)** Preseq library
1203 complexity estimation of H3K27ac HiChIP libraries from 25 million and 50 thousand
1204 mES cells.

1205

1206 **Supplementary Figure 4. H3K27ac HiChIP biological replicates from primary**
1207 **sorted T cells are highly reproducible. (A)** FACS strategy for Naïve, T_{H17}, and T_{reg}
1208 cells starting from human peripheral blood. Post-sort validation was used to ensure
1209 purity of T cell subtypes. Number represents percent of cells within that gate. **(B)** KR
1210 balanced interaction map of T cell subtype biological replicates. **(C)** Read support
1211 reproducibility of loops between H3K27ac HiChIP biological replicates in Naïve, T_{H17},
1212 and T_{reg} cells. **(D)** Aggregate peak analysis of loops in Naïve, T_{H17}, and T_{reg} H3K27ac
1213 HiChIP libraries.

1214

1215 **Supplementary Figure 5. Validation of HiChIP-identified *CD69* distal enhancers**
1216 **with CRISPR activation.** CRISPRa validation in Jurkat cells of *CD69* distal enhancers.
1217 *CD69* protein levels are shown for individual sgRNAs tiling H3K27ac HiChIP-identified
1218 distal *CD69* enhancers relative to the *KLRF2* promoter as a locus negative control and a
1219 non-targeting negative control.

1220

1221 **Supplementary Figure 6. Global enhancer connectome characterization in T cell**
1222 **differentiation. (A)** ChromHMM classification of union T cell loop anchors. **(B)** Contact
1223 distance distribution of union T cell loops. **(C)** Agreement in residual signal observed

1224 between sample signals per loop after removing imputed shared signal, calibrated by a
1225 null distribution of random pairings of loops. QQ plot shows modest enrichment above
1226 random pairings. PCA on residual signal clusters samples first by Naive vs Memory cell
1227 types (PC1), and then by donor identity (PC2, 3). **(D)** Overlap of differential interactions
1228 between Naïve, T_{H17} , and T_{reg} subtypes. Biased interactions were obtained by
1229 performing pairwise comparisons between T cell types and analyzing the top 5%
1230 enriched and top 5% depleted EIS in each T cell subtype. **(E)** ChromHMM annotation of
1231 total loops, differential loops, and shared loops in all three T cell subtypes. O
1232 corresponds to other loop anchors not classified as enhancer or promoter. **(F)** Number
1233 of connections for different classes of loop elements. **(G)** Quantification of promoters
1234 skipped before an enhancer reaches its loop target.

1235

1236 **Supplementary Figure 7. Positioning of differential HiChIP contacts in gene**
1237 **dense chromosomes. (A)** Distribution of T cell subtype differential HiChIP contacts
1238 across different chromosomes compared to the distribution of all loops. **(B)** Correlation
1239 of differential loop density with gene density and GC content.

1240

1241 **Supplementary Figure 8. Characterization of conformational landscapes**
1242 **surrounding key T cell regulatory factors. (A – C)** Virtual 4C interaction profiles
1243 anchored at the promoters of canonical Naïve, T_{H17} , and T_{reg} regulatory factors.

1244

1245 **Supplementary Figure 9. Chromosome conformation dynamics of canonical T**
1246 **cell regulatory factors. (A – C)** Delta interaction maps focused around known Naïve,
1247 T_{H17} , and T_{reg} regulatory factors.

1248

1249 **Supplementary Figure 10. Contribution of H3K27ac ChIP and chromosome**
1250 **conformation to HiChIP EIS. (A)** (Left) Proportion of H3K27ac ChIP peaks within EIS
1251 differential loop anchors that are cell-type specific (\log_2 fold change > 1) or shared
1252 across all three subtypes. (Right) Global correlation of EIS and H3K27ac ChIP fold-
1253 change in different T cell subset pairwise comparisons. **(B)** Same as (A), but using
1254 HiChIP 1D differential signal at EIS biased loop anchors. **(C)** Overlap of H3K27ac
1255 HiChIP and bins of Hi-C loops with increasing T cell subset and GM H3K27ac ChIP-seq
1256 signal. **(D)** Overlap of $CD4^+$ Capture Hi-C¹⁴ with total and differential T cell subset
1257 HiChIP loops. **(E)** T_{reg} -specific loops at the *LRRC32* promoter not observed in other
1258 H3K27ac HiChIP T cell subsets nor in $CD4^+$ Capture Hi-C data¹⁴.

1259

1260 **Supplementary Figure 11. Enrichment of autoimmune SNPs in T cell HiChIP loop**
1261 **anchors. (A)** Enrichment of specific PICS autoimmune disease and non-immune SNPs
1262 in anchors of loops called by Juicer and Fit-Hi-C compared to a background shuffled
1263 loop set. **(B)** Enrichment of all PICS autoimmune disease and non-immune SNPs in T
1264 cell subset biased loop anchors and all anchors compared to a background shuffled
1265 loop set.

1266

1267 **Supplementary Figure 12. T cell subtype HiChIP specificity of autoimmune SNPs.**

1268 **(A)** H3K27ac HiChIP signal bias in T cell subsets for PICS SNP-TSS pairs grouped by
1269 each SNP's presence in cell type-specific or shared H3K27ac ChIP peaks up to 8 kb
1270 away. **(B)** H3K27ac HiChIP signal bias in T cell subsets for PICS SNP-TSS pairs
1271 grouped by each SNP's presence in cell type-specific or shared H3K27ac ChIP peaks
1272 up to 2.5 kb away. **(C)** H3K27ac HiChIP signal bias in GM, K562, and My-La cell lines
1273 for PICS SNP-TSS pairs grouped by each SNP's presence in T cell subset-specific or
1274 shared H3K27ac ChIP peaks up to 8 kb away. **(D)** H3K27ac HiChIP signal bias in T cell
1275 subsets for GRASP SNP-TSS pairs grouped by each SNP's presence in cell type-
1276 specific or shared H3K27ac ChIP peaks up to 2.5 kb away. **(E)** Average number of
1277 HiChIP gene targets for non-genic autoimmune disease and non-immune SNPs. **(F)**
1278 Quantification of promoters skipped before a SNP reaches its gene target. **(G)**
1279 Quantification of SNP HiChIP gene targets in autoimmune disease.

1280 **Supplementary Figure 13. Validation of HiChIP signal at SNP-eQTL contacts. (A)**

1281 Validation of HiChIP signal at SNP-TSS pairs using interaction profiles of eQTL SNPs to
1282 ensure they contact their associated target gene promoter. **(B)** Interaction profiles of
1283 CRISPRi-validated loci in My-La.

1284 **Supplementary Figure 14. H3K27ac HiChIP fine-mapping of GWAS variants in**

1285 **haplotype blocks. (A)** Global validation of HiChIP signal at putatively causal SNPs
1286 versus corresponding SNPs in LD ($r^2 \geq 0.8$) for Naïve and T_{reg} cell subtypes. SNP-TSS
1287 pairs were generated from published fine-mapped datasets, compared to a distance-
1288 matched SNP-TSS pair set in the same LD block. **(B)** Interaction profile of the *SATB1*
1289 promoter, and a 1 kb resolution visualization of the SNP-containing enhancer of interest.
1290 Changes in bias between 5 kb and 1 kb resolution reflects EIS focused 1 kb around the
1291 *SATB1* TSS and specific SNPs within the enhancer. LD SNPs ($r^2 \geq 0.8$) correspond to
1292 GRASP SNPs (genome-wide significance p-value $< 10^{-8}$). The highlighted SNP is a
1293 PICS closest to focal EIS to *SATB1*.

1294 **Supplementary Figure 15. Chromatin interaction landscape of the 9p21.3**

1295 **cardiovascular disease risk locus.** HCASMC v4C interaction profiles focused around
1296 the promoters of *CDKN2A*, *CDKN2B*, and *ANRIL* within the 9p21.3 locus.

1297 **Supplementary Table 1. HiChIP data processing metrics.** HiC-Pro mapping, Hi-C

1298 filtering, duplicate removal, and interaction length statistics for all HiChIP libraries.

1299 **Supplementary Table 2. HiCCUPS high confidence loop calls.** High confidence loop

1300 calls for all HiChIP libraries.

1301

1302 **Supplementary Table 3. HiCCUPS differential EIS in T cell subtypes by edgeR.**

1303 High confidence loop calls in T cell subsets with edgeR significance and fold-change for
1304 pair-wise comparisons.

1305

1310 **Supplementary Table 4. HiCCUPS differential EIS in T cell subtypes.** Top 5% of
1311 EIS ranked by cell-type bias for each pair-wise comparison between different T cell
1312 subtypes.

1313
1314 **Supplementary Table 5. HiChIP gene targets of autoimmune and CAD SNPs.** SNP
1315 type (within gene, at TSS, or intergenic), associated disease, and corresponding loop
1316 annotated with the HiChIP gene target. Included are edgeR significance and fold-
1317 change for cell-type comparisons of interest.

1318
1319 **Supplementary Table 6. sgRNA and primer oligonucleotide sequences.** sgRNA
1320 and primer sequences used throughout the study.

1321
1322 **DATA AVAILABILITY STATEMENT**

1323 Raw and processed data available at NCBI Gene Expression Omnibus, accession
1324 number GSE101498.

1325
1326 T cell ATAC and HiChIP datasets can be visualized in the WashU Epigenome Browser
1327 with the following link:
1328 <http://epigenomegateway.wustl.edu/browser/?genome=hg19&session=YAlzYBfrl9&statusId=1698051079>

1329
1330
1331 **COMPETING FINANCIAL INTEREST**

1332 The authors declare no competing financial interests.

1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353

1354 **METHODS-ONLY REFERENCES**

1355

1356 50. Index Switching Causes “Spreading-Of-Signal” Among Multiplexed Samples In

1357 Illumina HiSeq 4000 DNA Sequencing | bioRxiv. Available at:

1358 <http://biorxiv.org/content/early/2017/04/09/125724>. (Accessed: 19th May 2017)

1359 51. Servant, N. *et al.* HiC-Pro: an optimized and flexible pipeline for Hi-C data

1360 processing. *Genome Biol.* **16**, 259 (2015).

1361 52. Gjoneska, E. *et al.* Conserved epigenomic signals in mice and humans reveal immune

1362 basis of Alzheimer’s disease. *Nature* **518**, 365–369 (2015).

1363 53. Kagey, M. H. *et al.* Mediator and cohesin connect gene expression and chromatin

1364 architecture. *Nature* **467**, 430–435 (2010).

1365 54. Yue, F. *et al.* A comparative encyclopedia of DNA elements in the mouse genome.

1366 *Nature* **515**, 355–364 (2014).

1367 55. Bonnal, R. J. P. *et al.* De novo transcriptome profiling of highly purified human

1368 lymphocytes primary cells. *Sci. Data* **2**, 150051 (2015).

1369 56. Ay, F., Bailey, T. L. & Noble, W. S. Statistical confidence estimation for Hi-C data

1370 reveals regulatory chromatin contacts. *Genome Res.* gr.160374.113 (2014).

1371 doi:10.1101/gr.160374.113

1372 57. Adamson, B. *et al.* A Multiplexed Single-Cell CRISPR Screening Platform Enables

1373 Systematic Dissection of the Unfolded Protein Response. *Cell* **167**, 1867–1882.e21

1374 (2016).

1375 58. Gilbert, L. A. *et al.* Genome-Scale CRISPR-Mediated Control of Gene Repression and

1376 Activation. *Cell* **159**, 647–661 (2014).


1377 59. Doench, J. G. *et al.* Optimized sgRNA design to maximize activity and minimize off-
1378 target effects of CRISPR-Cas9. *Nat. Biotechnol.* **34**, 184–191 (2016).

1379 60. Hsu, P. D. *et al.* DNA targeting specificity of RNA-guided Cas9 nucleases. *Nat.*
1380 *Biotechnol.* **31**, 827–832 (2013).


1381 61. Horlbeck, M. A. *et al.* Nucleosomes impede Cas9 access to DNA in vivo and in vitro.
1382 *eLife* **5**, (2016).

1383


Mumpach et al. (CHANG) Figure 1




a




b



c




d




e


GM12878
CRISPRi
E-P Validation




Cell Growth




f




g




a




b






c




d




e




f





g



g







Mumbach et al. (CHANG), Figure 6

